Resources
About Us
Home Report
Store
Europe Continuous Bioprocessing Market
Europe Continuous Bioprocessing Market by Product (Filtration, Chromatography, Centrifuges, Consumables), Application (Commercial {Vaccines, Monoclonal Antibodies}, R&D), End User (Pharmaceuticals, Biotechnology, CROs) - Forecast to 2030
Report ID:MRHC - 104922 Pages: 110 Jul-2024 Formats*: PDF Category: Healthcare Delivery: 24 to 72 HoursThe Europe Continuous Bioprocessing Market is expected to grow at a CAGR of 19.1% from 2024 to 2030 to reach $206.1 million by 2030. Continuous manufacturing is an emerging trend spanning various industries. From automotive to paper, businesses are embracing continuous manufacturing to enhance efficiency and bolster profits. The shift from batch to continuous manufacturing is gaining traction in the biopharmaceuticals sector due to the surge in demand for intricate therapies and heightened market competition. Continuous bioprocessing is increasingly being adopted due to its agility, flexibility, efficiency, and robustness. This approach streamlines processes by minimizing steps, utilizing compact facilities and equipment, and enhancing product quality to facilitate real-time release.
The growth of the continuous bioprocessing market in Europe is attributed to recent product launches and advances in the continuous bioprocessing space, gradual adoption of continuous manufacturing, and initiatives supporting the adoption of biopharmaceuticals. Furthermore, the shift towards bioprocessing 4.0 and the rising adoption of personalized medicines are expected to provide significant market growth opportunities.
However, the limitations of continuous bioprocessing may restrain the growth of this market. Additionally, manufacturers’ hesitation to shift from batch manufacturing to continuous manufacturing poses challenges to the market players.
Click here to: Get Free Sample Pages of this Report
Recent Product Launches and Advances Drive Europe Continuous Bioprocessing Market
Over the years, significant strides have been taken in bioprocessing to achieve cost reductions, enhance product yield, and seamlessly integrate upstream and downstream processing. Progress in upstream processing has been concentrated on essential aspects such as elevating volumetric productivity through process intensification, amplifying cell-specific productivity, leveraging cellular and molecular biology, and expediting process development timelines.
Bioprocessing operations have also led to continuous improvements in cell expression systems and the development and improvement of disposable bioreactors impacting bioprocessing operations, leading to new product launches. For instance,
- In February 2022, Sartorius AG (Germany) completed the acquisition of Novasep Holding SAS (France). The portfolio acquired comprises chromatography systems primarily suited for smaller biomolecules, such as oligonucleotides, peptides, and insulin, and innovative systems for continuous biologics manufacturing.
- In November 2020, Eppendorf AG (Germany) upgraded its well-known Eppendorf ThermoMixer C with a heating/cooling/mixing function to develop the new exchangeable thermoblock, SmartBlock cryo thaw, that carries out the reliable and reproducible thawing of cells from frozen storage temperatures to over 370C.
- In March 2020, Sartorius AG (Germany) launched the next-generation BIOSTAT STR Generation 3 and BIOBRAIN automation platform for addressing the critical requirements and complexity of biologics manufacturing.
Thus, the increasing product launches and innovation are driving the growth of the continuous bioprocessing market in Europe.
Capacity Expansion by Vendors Supports the Europe Continuous Bioprocessing Market
The demand for innovative manufacturing methods like continuous processing is rising due to the increasing influx of vaccine and therapeutic candidates in the pipeline. Furthermore, the impact of COVID-19 has increased the need for extensive-volume bioproduction. In response, numerous vendors are scaling up their manufacturing and production capacities to cater to the escalating demand for biopharmaceutical products. For instance,
- In September 2022, Eppendorf AG (Germany) expanded its bioprocess site in Jülich, Germany, to increase its bioprocess solutions production capacity by up to 20%.
- In June 2022, Merck KGaA (Germany) expanded the production capacity of its Life Science business segment—Highly Potent Active Pharmaceutical Ingredients (HPAPI), with the expansion of its facility in Wisconsin, U.S., by investing USD 62 million (EUR 59 million).
- In September 2022, Merck KGaA (Germany) expanded its manufacturing capacity for the Mobius single-use portfolio by investing USD 137 million (EUR 130 million) in Molsheim, France.
Key Findings in the Europe Continuous Bioprocessing Market Study:
In 2024, the filtration systems and consumables segment is expected to account for the largest share of the Europe continuous bioprocessing market
In 2024, the filtration systems and consumables segment is estimated to account for the largest share of the Europe continuous bioprocessing market. Filtration stands as a preferred purification method in the biopharmaceutical sector. The surge in advanced filtration systems and consumables, such as disposable or single-use systems, combined with the filters' reusability across various bioprocessing steps, contributes to the significant market share of this segment.
In 2024, the commercial application segment is expected to account for the largest share of the Europe continuous bioprocessing market
In 2024, the commercial application segment is estimated to account for the largest share of the Europe continuous bioprocessing market. Growing initiatives supporting the adoption of biopharmaceuticals, rising biopharmaceutical manufacturing outsourcing, growing investments in constructing facilities compatible with continuous bioprocessing for the commercial manufacture of biopharmaceuticals, and accelerated developments in personalized therapies drive the adoption of continuous bioprocessing for commercial application. For instance, in April 2021, Evotec (Germany) started the construction of its new J.POD 2 EU cGMP biomanufacturing facility in France. The new facility, Evotec’s first in Europe, will offer capacity, flexibility, and quality for biotherapeutic development and manufacturing while utilizing its subsidiary Just – Evotec Biologics’ technology that employs small, automated, highly intensified, and continuous bioprocessing operations inside cleanrooms.
In 2024, the pharmaceutical and biotechnology companies segment is expected to account for the largest share of the Europe continuous bioprocessing market
In 2024, the pharmaceutical and biotechnology companies segment is estimated to account for the largest share of the Europe continuous bioprocessing market. The large share of this segment is attributed to factors such as the transition of pharma and biopharma manufacturers from batch to continuous processing, regulatory authorities' increasing emphasis on continuous bioprocessing, and the rising investments directed towards the integration of continuous processing technologies.
Germany to account for the largest market share in 2024
In 2024, Germany is estimated to dominate the Europe Continuous Bioprocessing market. Germany’s significant market share is primarily attributed to favorable initiatives supporting the adoption of biosimilars, a strong biopharma market compared to other European countries, and the presence of leading players in Germany.
Key Players
The report includes a competitive landscape based on the key growth strategies adopted by leading market players in the past four years. The key players profiled in the Europe Continuous Bioprocessing market study are 3M Company (U.S.), Cytiva (U.S.), Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), Sartorius AG (Germany), Repligen Corporation (U.S.), Eppendorf AG (Germany), Applikon Biotechnology (Netherlands), Pall Corporation (U.S.), Solida Biotech GmBH (Germany), Electrolab Biotech Limited (U.K.), Biowest (France), and Bionet (U.S.).
Scope of the Report:
Europe Continuous Bioprocessing Market Assessment, by Product
- Filtration Systems and Consumables
- Chromatography Systems and Consumables
- Cell Culture Media, Buffers, and Reagents
- Incubators and Shakers
- Bioreactors
- Centrifuges
- Sterilizers
- Other Instruments and Consumables
Europe Continuous Bioprocessing Market Assessment, by Application
- Commercial Applications
- Monoclonal Antibodies (MAB) Production
- Cell and Gene Therapy Production
- Vaccine Manufacturing
- Plasma Fractionation
- Recombinant Protein Production
- Research & Development (R&D)
Europe Continuous Bioprocessing Market Assessment, by End User
- Pharmaceutical and Biotechnology Companies
- Contract Development and Manufacturing Organizations (CDMOS) and Contract Research Organizations (CROS)
- Academic and Research Institutes
Europe Continuous Bioprocessing Market Assessment, by Country
- Germany
- U.K.
- France
- Spain
- Italy
- Switzerland
- Netherlands
- Belgium
- Denmark
- Ireland
- Rest of Europe
Key questions answered in the report:
This report covers the market sizes & forecasts for various products, applications, end user, and geography. It also involves the value analysis of various segments and sub-segments of continuous bioprocessing at the country level.
The Europe continuous bioprocessing market is projected to reach $206.1 million by 2030, at a CAGR of 19.1% during the forecast period of 2024–2030.
Based on product, in 2024, the filtration systems and consumables segment is estimated to account for the largest share of the Europe continuous bioprocessing market.
The growth of this market is attributed to factors such as recent product launches and advances in the continuous bioprocessing space, gradual adoption of continuous manufacturing, and initiatives supporting the adoption of biopharmaceuticals. Furthermore, the shift towards bioprocessing 4.0 and the rising adoption of personalized medicines are expected to provide significant market growth opportunities.
The limitations of continuous bioprocessing may restrain the growth of this market.
The key players operating in the Europe continuous bioprocessing market are 3M Company (U.S.), Cytiva (U.S.), Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), Sartorius AG (Germany), Repligen Corporation (U.S.), Eppendorf AG (Germany), Applikon Biotechnology (Netherlands), Pall Corporation (U.S.), Solida Biotech GmBH (Germany), Electrolab Biotech Limited (U.K.), Biowest (France), and Bionet (U.S.).
The market in Germany is projected to register the highest growth rate during the forecast period and offer significant growth opportunities for the players operating in this market. The presence of key market players and rising government initiatives aimed at promoting the adoption of biosimilars are key factors driving the market’s growth in Germany.
1. Market Definition & Scope
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency and Limitation
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research / Interviews with Key Opinion Leaders of The Industry
2.3. Market Sizing and Forecast
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumptions for The Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Factors Affecting Market Growth
4.2.1. Drivers
4.2.1.1. Growing Adoption of Continuous Bioprocessing
4.2.1.2. Recent Product Launches and Advances in the Continuous Bioprocessing Space
4.2.1.3. Initiatives Supporting the Adoption of Biopharmaceuticals
4.2.2. Restraints
4.2.2.1. Limitations of Continuous Bioprocessing
4.2.3. Opportunities
4.2.3.1. Shift Towards Bioprocessing 4.0
4.2.3.2. Rising Adoption of Personalized Medicine
4.2.4. Challenges
4.2.4.1. Manufacturers' Reluctance to Shift from Batch Manufacturing to Continuous Manufacturing
4.3. Market Trends
4.4. Parent Market Analysis: Bioprocessing Equipment and Consumables Market
4.5. Porter's Five Forces Analysis
4.5.1. Bargaining Power of Buyers
4.5.2. Bargaining Power of Suppliers
4.5.3. Threat of Substitutes
4.5.4. Threat of New Entrants
4.5.5. Degree of Competition
5. Europe Continuous Bioprocessing Market Assessment—by Product
5.1. Overview
5.2. Filtration Systems and Consumables
5.3. Chromatography Systems and Consumables
5.4. Cell Culture Media, Buffers, and Reagents
5.5. Incubators and Shakers
5.6. Bioreactors
5.7. Centrifuges
5.8. Sterilizers
5.9. Other Instruments and Consumables
6. Europe Continuous Bioprocessing Market Assessment—by Application
6.1. Overview
6.2. Commercial Applications
6.2.1. Monoclonal Antibodies (mAbs) Production
6.2.2. Cell and Gene Therapy Production
6.2.3. Vaccine Manufacturing
6.2.4. Plasma Fractionation
6.2.5. Recombinant Protein Production
6.3. Research & Development (R&D)
7. Europe Continuous Bioprocessing Market Assessment—by End User
7.1. Overview
7.2. Pharmaceutical and Biotechnology Companies
7.3. Contract Development and Manufacturing Organizations (CDMOS) and Contract Research Organizations (CROS)
7.4. Academic and Research Institutes
8. Europe Continuous Bioprocessing Market Assessment—by Country
8.1. Overview
8.2. Germany
8.3. U.K.
8.4. France
8.5. Spain
8.6. Italy
8.7. Switzerland
8.8. Netherlands
8.9. Belgium
8.10. Denmark
8.11. Ireland
8.12. Rest of Europe (RoE)
9. Competition Analysis
9.1. Overview
9.2. Key Growth Strategies
9.3. Competitive Benchmarking
9.4. Competitive Dashboard
9.4.1. Industry Leaders
9.4.2. Market Differentiators
9.4.3. Vanguards
9.4.4. Emerging Companies
9.5. Market Share Analysis, by Key Players (2022)
10. Company Profiles (Company Overview, Financial Overview, Product Portfolio, and Strategic Developments)
10.1. 3M Company
10.2. Thermo Fisher Scientific Inc.
10.3. Sartorius AG
10.4. Eppendorf AG
10.5. Pall Corporation
10.6. Cytiva
10.7. Merck KGAA
10.8. Repligen Corporation
10.9. Applikon Biotechnology
10.10. Bionet
10.11. Solida Biotech GmBH
10.12. Electrolab Biotech Limited
10.13. Biowest
(Note: SWOT analysis is provided for the top 5 companies)
11. Appendix
11.1. Available Customization
11.2. Related Reports
List of Table
Table 1 Europe Continuous Bioprocessing Market, by Product, 2021-2030 (USD Million)
Table 2 Key Companies Offering Filtration Systems and Consumables
Table 3 Filtration Systems and Consumables Market, by Country, 2021-2030 (USD Million)
Table 4 Key Companies Offering Chromatography Systems and Consumables
Table 5 Cell Culture Media, Buffers, and Reagents Market, by Country, 2021-2030 (USD Million)
Table 6 Key Companies Offering Cell Culture Media, Buffers, and Reagents
Table 7 Incubators and Shakers Market, by Country, 2021-2030 (USD Million)
Table 8 Key Companies Offering Incubators and Shakers
Table 9 Bioreactors Market, by Country, 2021-2030 (USD Million)
Table 10 Key Companies Offering Bioreactors
Table 11 Incubators Market, by Country, 2021-2030 (USD Million)
Table 12 Key Companies Offering Incubators
Table 13 Centrifuges Market, by Country, 2021-2030 (USD Million)
Table 14 Key Companies Offering Centrifuges
Table 15 Sterilizers Market, by Country, 2021-2030 (USD Million)
Table 16 Key Companies Offering Sterilizers
Table 17 Other Instruments and Consumables Market, by Country, 2021-2030 (USD Million)
Table 18 Key Companies Offering Other Instruments and Consumables
Table 19 Europe Continuous Bioprocessing Market, by Application, 2021-2030 (USD Million)
Table 20 Europe Continuous Bioprocessing Market for Commercial Applications, by Country, 2021-2030 (USD Million)
Table 21 Europe Continuous Bioprocessing Market for Monoclonal Antibodies Production, by Country, 2021-2030 (USD Million)
Table 22 Europe Continuous Bioprocessing Market for Cell and Gene Therapy Production, by Country, 2021-2030 (USD Million)
Table 23 Europe Continuous Bioprocessing Market for Plasma Fractionation, by Country, 2021-2030 (USD Million)
Table 24 Europe Continuous Bioprocessing Market for Recombinant Protein Production, by Country, 2021-2030 (USD Million)
Table 25 Europe Continuous Bioprocessing Market for R&D Application, by Country, 2021-2030 (USD Million)
Table 26 Europe Continuous Bioprocessing Market, by End User, 2021-2030 (USD Million)
Table 27 Europe Continuous Bioprocessing Market for Pharmaceutical and Biotechnology Companies, by Country, 2021-2030 (USD Million)
Table 28 Europe Continuous Bioprocessing Market for Contract Development and Manufacturing Organizations and Contract Research Organizations, by Country, 2021-2030 (USD Million)
Table 29 Europe Continuous Bioprocessing Market for Academic and Research Institutes, by Country, 2021-2030 (USD Million)
Table 30 Europe: Continuous Bioprocessing Market, by Country, 2021-2030 (USD Million)
Table 31 Europe: Continuous Bioprocessing Market, by Product, 2021-2030 (USD Million)
Table 32 Europe: Continuous Bioprocessing Market, by Application, 2021-2030 (USD Million)
Table 33 Europe: Continuous Bioprocessing Market for Commercial Applications, by Type, 2021-2030 (USD Million)
Table 34 Europe: Continuous Bioprocessing Market, by End User, 2021-2030 (USD Million)
Table 35 Germany: Continuous Bioprocessing Market, by Product, 2021-2030 (USD Million)
Table 36 Germany: Continuous Bioprocessing Market, by Application, 2021-2030 (USD Million)
Table 37 Germany: Continuous Bioprocessing Market for Commercial Applications, by Type, 2021-2030 (USD Million)
Table 38 Germany: Continuous Bioprocessing Market, by End User, 2021-2030 (USD Million)
Table 39 U.K.: Continuous Bioprocessing Market, by Product, 2021-2030 (USD Million)
Table 40 U.K.: Continuous Bioprocessing Market, by Application, 2021-2030 (USD Million)
Table 41 U.K.: Continuous Bioprocessing Market for Commercial Applications, by Type, 2021-2030 (USD Million)
Table 42 U.K.: Continuous Bioprocessing Market, by End User, 2021-2030 (USD Million)
Table 43 France: Continuous Bioprocessing Market, by Product, 2021-2030 (USD Million)
Table 44 France: Continuous Bioprocessing Market, by Application, 2021-2030 (USD Million)
Table 45 France: Continuous Bioprocessing Market for Commercial Applications, by Type, 2021-2030 (USD Million)
Table 46 France: Continuous Bioprocessing Market, by End User, 2021-2030 (USD Million)
Table 47 Spain: Continuous Bioprocessing Market, by Product, 2021-2030 (USD Million)
Table 48 Spain: Continuous Bioprocessing Market, by Application, 2021-2030 (USD Million)
Table 49 Spain: Continuous Bioprocessing Market for Commercial Applications, by Type, 2021-2030 (USD Million)
Table 50 Spain: Continuous Bioprocessing Market, by End User, 2021-2030 (USD Million)
Table 51 Italy: Continuous Bioprocessing Market, by Product, 2021-2030 (USD Million)
Table 52 Italy: Continuous Bioprocessing Market, by Application, 2021-2030 (USD Million)
Table 53 Italy: Continuous Bioprocessing Market for Commercial Applications, by Type, 2021-2030 (USD Million)
Table 54 Italy: Continuous Bioprocessing Market, by End User, 2021-2030 (USD Million)
Table 55 Switzerland: Continuous Bioprocessing Market, by Product, 2021-2030 (USD Million)
Table 56 Switzerland: Continuous Bioprocessing Market, by Application, 2021-2030 (USD Million)
Table 57 Switzerland: Continuous Bioprocessing Market for Commercial Applications, by Type, 2021-2030 (USD Million)
Table 58 Switzerland: Continuous Bioprocessing Market, by End User, 2021-2030 (USD Million)
Table 59 Netherlands: Continuous Bioprocessing Market, by Product, 2021-2030 (USD Million)
Table 60 Netherlands: Continuous Bioprocessing Market, by Application, 2021-2030 (USD Million)
Table 61 Netherlands: Continuous Bioprocessing Market for Commercial Applications, by Type, 2021-2030 (USD Million)
Table 62 Netherlands: Continuous Bioprocessing Market, by End User, 2021-2030 (USD Million)
Table 63 Belgium: Continuous Bioprocessing Market, by Product, 2021-2030 (USD Million)
Table 64 Belgium: Continuous Bioprocessing Market, by Application, 2021-2030 (USD Million)
Table 65 Belgium: Continuous Bioprocessing Market for Commercial Applications, by Type, 2021-2030 (USD Million)
Table 66 Belgium: Continuous Bioprocessing Market, by End User, 2021-2030 (USD Million)
Table 67 Denmark: Continuous Bioprocessing Market, by Product, 2021-2030 (USD Million)
Table 68 Denmark: Continuous Bioprocessing Market, by Application, 2021-2030 (USD Million)
Table 69 Denmark: Continuous Bioprocessing Market for Commercial Applications, by Type, 2021-2030 (USD Million)
Table 70 Denmark: Continuous Bioprocessing Market, by End User, 2021-2030 (USD Million)
Table 71 Ireland: Continuous Bioprocessing Market, by Product, 2021-2030 (USD Million)
Table 72 Ireland: Continuous Bioprocessing Market, by Application, 2021-2030 (USD Million)
Table 73 Ireland: Continuous Bioprocessing Market for Commercial Applications, by Type, 2021-2030 (USD Million)
Table 74 Ireland: Continuous Bioprocessing Market, by End User, 2021-2030 (USD Million)
Table 75 RoE: Continuous Bioprocessing Market, by Product, 2021-2030 (USD Million)
Table 76 RoE: Continuous Bioprocessing Market, by Application, 2021-2030 (USD Million)
Table 77 RoE: Continuous Bioprocessing Market for Commercial Applications, by Type, 2021-2030 (USD Million)
Table 78 RoE: Continuous Bioprocessing Market, by End User, 2021-2030 (USD Million)
Table 79 Recent Developments, by Company, 2020-2024
List of Figures
Figure 1 Research Process
Figure 2 Secondary Sources Referenced for This Study
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
Figure 6 Market Sizing and Growth Forecast Approach
Figure 7 Europe Continuous Bioprocessing Market, by Product, 2021-2030 (USD Million)
Figure 8 Europe Continuous Bioprocessing Market, by Application, 2021-2030 (USD Million)
Figure 9 Europe Continuous Bioprocessing Market, by End User, 2021-2030 (USD Million)
Figure 10 Europe Continuous Bioprocessing Market, by Country, 2024 Vs. 2030 (USD Million)
Figure 11 Impact Analysis: Europe Continuous Bioprocessing Market
Figure 12 Europe Continuous Bioprocessing Market, by Product, 2024 Vs. 2030 (USD Million)
Figure 13 Europe Continuous Bioprocessing Market, by Application, 2024 Vs. 2030 (USD Million)
Figure 14 Europe Continuous Bioprocessing Market, by End User, 2024 Vs. 2030 (USD Million)
Figure 15 Europe Continuous Bioprocessing Market, by Country, 2021-2030 (USD Million)
Figure 16 Europe: Telehealth Market Snapshot
Figure 17 Competitive Dashboard: Europe Continuous Bioprocessing Market
Figure 18 3M: Financial Overview (2022)
Figure 19 Thermo Fisher Scientific: Financial Overview (2022)
Figure 20 Sartorius AG: Financial Overview (2022)
Figure 21 Eppendorf AG: Financial Overview (2021)
Figure 22 Danaher Corporation: Financial Overview (2022)
Figure 23 General Electric Company: Financial Overview (2022)
Figure 24 Merck KGaA: Financial Overview (2022)
Figure 25 Getinge AB: Financial Overview (2022)
Author Name:
Proudly Partnering With Enterprises Around the Globe
Quick Contact
Related Reports
Europe LIMS Market - Opportunity Analysis and Industry Forecast (2024-2030)
Published Date: Jul-2024
Europe NGS Market - Opportunity Analysis and Industry Forecasts (2024-2030)
Published Date: Jul-2024
Continuous Bioprocessing Market - Global Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: Mar-2024
Continuous Glucose Monitoring Market - Global Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: Jan-2024
